The IARC handbook noted that HPV testing is likely to achieve the same reduction in incidence of invasive disease that could be achieved with longer inter screening interval than the intervals recommended for routine cytological screening. Multiple large, well-controlled screening trials have clearly demonstrated that HPV testing is considerably more sensitive and reproducible than cytology and only slightly less specific when used in women 30 years of age and older. Triage of borderline or ASCUS pap smears, Primary screening for pre-invasive disease and “test of cure” for those women that have previously under gone treatment for high grade disease is the possible role of HPV Testing. However age is an important defining factor. For Primary Screening, the sensitivity is greater than that of cervical cytology. The Digene HPV Test is based on Signal Amplification system while the Polymerase Chain Reaction (PCR) test is generally referred to as target amplification test. HPV testing is most required in the developing world where the burden of cervical cancer is very high. Since cost and complicated technology are significant factors, new test are being developed. Qiagen Care HPV test is now introduced which is inexpensive, quick and requires low laboratory support.